Up-front alternative donor HCT in severe aplastic anemia: gaps and opportunities to translate evidence into practice
Abstract: Severe aplastic anemia (SAA) is a rare and life-threatening bone marrow failure disorder. Immunosuppressive therapy (IST) with antithymocyte globulin and cyclosporine has long been a frontline treatment option in SAA; however, its limited durability and risk of long-term complications such...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , , , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Elsevier
2025-09-01
|
| Ráidu: | Blood Advances |
| Liŋkkat: | http://www.sciencedirect.com/science/article/pii/S2473952925003568 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
